LABMD, Inc. v. Federal Trade Commission

776 F.3d 1275, 2015 WL 233072, 2015 U.S. App. LEXIS 781
CourtCourt of Appeals for the Eleventh Circuit
DecidedJanuary 20, 2015
Docket14-12144
StatusPublished
Cited by14 cases

This text of 776 F.3d 1275 (LABMD, Inc. v. Federal Trade Commission) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
LABMD, Inc. v. Federal Trade Commission, 776 F.3d 1275, 2015 WL 233072, 2015 U.S. App. LEXIS 781 (11th Cir. 2015).

Opinion

*1277 MARTIN, Circuit Judge:

LabMD, Inc. is an Atlanta-based laboratory that performed cancer-detection testing services for doctors. After the Federal Trade Commission (FTC) discovered that LabMD patient information files were available on a peer-to-peer file-sharing network, it launched an investigation .into LabMD’s data-security practices. The investigation persisted for three years, leading LabMD’s CEO, Michael Daugherty, to publicly criticize the FTC’s actions. Shortly after Mr. Daugherty posted an online trailer for his book, “The Devil Inside the Beltway,” which he says exposes corruption in the federal government, the FTC filed an administrative complaint against the company. The administrative proceeding is ongoing.

This appeal addresses the District Court’s dismissal of LabMD’s challenges to the FTC’s ability to regulate and conduct enforcement proceedings in the area of healthcare data privacy. LabMD argues that the FTC’s enforcement action violates the Administrative Procedure Act (APA), is ultra vires, and is unconstitutional.

Before we can reach the merits of LabMD’s claims, we must first face the central question of whether the District Court has subject-matter jurisdiction to consider LabMD’s challenges while the administrative proceeding is ongoing. Because we hold that the FTC’s Order denying LabMD’s motion to dismiss was not a “final agency action,” as is required of claims made under the APA, those claims were properly dismissed. And because we conclude that LabMD’s other claims — that the FTC’s actions were ultra vires and unconstitutional — are intertwined with its APA claim for relief and may only be heard at the end of the administrative proceeding, we affirm the District Court’s order dismissing the case for lack of subject-matter jurisdiction.

I.

In 2008, internet-security company Tiv-ersa, Inc. notified LabMD that it had obtained sensitive patient information from LabMD. Under circumstances that remain hotly disputed by the parties, the FTC learned about the possible breach of security involving patient information and began an investigation into LabMD’s data-security practices in 2010. On July 19, 2013, Mr. Daugherty posted an online trailer to his book highlighting corruption in the federal government, including specific claims about the FTC. Three days after Mr. Daugherty posted the trailer online, the FTC gave notice of its intent to file a complaint against LabMD.

In August 2013, the FTC filed its administrative complaint, alleging that LabMD violated Section 5 of the FTC Act by engaging in an “unfair ... act[ ] or practice[ ]” by failing to prevent unauthorized access to its patient information. LabMD moved to dismiss the FTC Complaint, which the FTC denied in a January 2014 Order. LabMD next filed suit in the District Court for the District of Columbia, seeking an injunction to stay the administrative action from going forward on the grounds that it was an improper expansion of FTC jurisdiction, was retaliatory, and violated the Due Process Clause. LabMD v. FTC, No. 1:13-cv-1787 (D.D.C. Nov. 14, 2013). LabMD filed a similar action in this Court, making the same allegations. LabMD Inc. v. FTC, No. 13-15267-F (11th Cir. Feb. 18, 2014). We denied LabMD’s claim, citing our lack of jurisdiction over a non-final agency action, but we declined to address whether the District Court could hear any of the claims. Id. LabMD voluntarily dismissed its District of Columbia suit.

On March 20, 2014, LabMD filed this suit in the Northern District of Georgia, alleging that: (1) the FTC’s administrative *1278 action against LabMD is arbitrary and capricious in violation of the APA because the FTC has no authority to regulate protected health information (PHI); (2) the action is ultra vires and exceeds its statutory authority; (3) the FTC’s application of Section 5 to LabMD’s security protocols violates the Due Process Clause of the U.S. Constitution because it did not provide fair notice or access to a fair tribunal and a hearing; and (4) the FTC violated LabMD’s First Amendment right to free speech. The FTC filed a motion to dismiss, which the District Court granted.

II.

We review de novo a district court’s grant of a motion to dismiss for lack of subject-matter jurisdiction. Cash v. Barnhart, 3 27 F.3d 1252, 1255 n. 4 (11th Cir.2003) (per curiam). The District Court dismissed LabMD’s APA claim for lack of subject-matter jurisdiction because the FTC’s Order denying dismissal was not a final order. The District Court also dismissed the related constitutional and ultra vires claims as premature. We first turn to LabMD’s challenge under the APA. LabMD argues that the Complaint and Order were sufficiently final to confer subject-matter jurisdiction over its APA claim. We cannot agree.

According to the APA, “final agency action for which there is no other adequate remedy in a court [is] subject to judicial review.” 5 U.S.C. § 704. Absent a final action, the courts are to exercise restraint so that the administrative agency may correct any errors by conducting its own internal appeals and by applying its own institutional expertise. The Supreme Court has held that an action must satisfy two requirements to be final: “First, the action must mark the consummation of the agency’s decisionmaking process—it must not be of a merely tentative or interlocutory nature. And second, the action must be one by which rights or obligations have been determined, or from which legal consequences will flow.” Bennett v. Spear, 520 U.S. 154, 177-78, 117 S.Ct. 1154, 1168, 137 L.Ed.2d 281 (1997) (internal citations and quotation marks omitted).

Under the Bennett standard, the Order and Complaint LabMD seeks to have us review are not final. First, neither document is a consummation of the agency’s decisionmaking process. LabMD suggests that these documents “effectively determined there would be legal consequences imposed on LabMD,” because the filing of an FTC complaint almost certainly leads to a cease-and-desist order. But, high odds of a cease-and-desist order coming from the FTC do not advance our ability to review the FTC actions. It is the nature of the action we must consider, and the Complaint and Order do not finally decide these issues. By definition, the denial of a motion to dismiss ensures that the proceeding will continue to a later, final order. In the same way, a complaint is just an initial document.

Next, no “direct and appreciable legal consequences” flowed from either FTC action, and “no rights or obligations have been determined,” because the agency proceeding is ongoing. See Bennett, 520 U.S. at 178, 117 S.Ct. at 1168-69. LabMD argues that, on two occasions, the FTC characterized its Order as final, and therefore we must accept it as such. First, the FTC described its Order here as a “definitive interpretation of the application of Section 5.” Second, the FTC sought Chevron 1 deference for this Order in an *1279 other case. See FTC v. Wyndham Worldwide Corp.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
776 F.3d 1275, 2015 WL 233072, 2015 U.S. App. LEXIS 781, Counsel Stack Legal Research, https://law.counselstack.com/opinion/labmd-inc-v-federal-trade-commission-ca11-2015.